Activity Summary:
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this lecture library, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this Clinical Clip activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.

Activity Summary:
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Activity Summary:
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These mini modules address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. To this end, it is critical that pediatric oncologists as well as other members of the multidisciplinary team neurologists caring for patients with NF1-PN are up to date on recent advances. In this podcast lecture library, Dr. Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Activity Summary:
Patients with plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1) experience considerable morbidity, a poor quality of life, and increased mortality. Research efforts have led to earlier diagnosis, new monitoring approaches, emerging treatment options, and considerations for surgical intervention. 

In this video presentation, Dr Armstrong uses a case-based discussion to address the heterogeneity and complexity of this condition as well as considerations for the use of emerging therapies when making individualized management decisions among diverse patients.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This podcast ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
Precision therapy has revolutionized the treatment of lung cancer and has made personalized treatment a reality. To this end, the therapeutic landscape for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations has been evolving rapidly. Indeed, ongoing studies are investigating novel agents and combinations that will play a role in earlier and subsequent treatment settings of EGFR mutated NSCLC and are also exploring the utility of additional biomarkers in guiding therapy in EGFR mutated advanced NSCLC. Considering a continual influx of such progress from ongoing trials, clinicians and healthcare professionals will need guidance from key opinion leaders in sifting through recent evidence and identifying practice-changing updates.

This clinical clip ensures clinicians are up-to-date on key data for NSCLC harboring EGFR mutations presented at the 2024 ASCO Annual Meeting in Chicago, IL May 31 – June 4, 2024 and aids learners in safely applying recent evidence into practice.

Activity Summary:
In this podcast series, Drs. Andrew Armstrong and Tanya Dorff will clarify the rationale and best-practice approaches for HRRm testing to guide therapeutic strategies in metastatic prostate cancer. Clinical case scenarios are used to enhance the learning experience and provide practical considerations to achieve improved outcomes among patients.

Activity Summary:
The most recent guidelines recommend germline and/or somatic homologous recombination repair (HRR) gene panel testing to identify patients with metastatic prostate cancer that can benefit from poly-ADP ribose polymerase (PARP) inhibitors. However, HRR gene mutation (HRRm) testing rates are low and as a result, many patients with metastatic prostate cancer are unable to avail of these new therapies that have the potential to improve survival outcomes. This has been attributed to limited awareness about testing, inadequate sample, challenges with reimbursement, lack of patient counseling, and costs. Improving clinician and allied healthcare professional familiarity with HRRm testing guidelines and implementation recommendations, is therefore of utmost importance.

In these Mini Modules, Drs. Andrew Armstrong and Tanya Dorff use a discussion and case-based format to clarify the rationale for HRRm testing in metastatic prostate cancer and ensure better integration of the latest guidelines for testing by addressing barriers. The overall aim is to enable appropriate utilization of HRRm testing to ultimately improve outcomes among patients.

Activity Summary:
Conversations and Cases in Oncology: Practice-Changing Updates in Systemic Treatment of Advanced Hepatocellular Carcinoma (HCC) is a roundtable discussion between leading experts to inform and guide on key updates. The expert faculty, Dr. Adam Burgoyne, Dr. Rachna Shroff and Dr. Mark Yarchoan, will discuss recent progress in different treatment settings of advanced HCC and provide insights into integrating new evidence into practice.

This activity will be supported by supplemental, downloadable slides as an educational resource.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a podcast discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Activity Summary:
Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO is a roundtable discussion between leading experts to inform and guide the safety and efficacy of trophoblast cell-surface antigen-directed antibody-drug conjugates (TROP2-directed ADCs) in different settings of non-small cell lung cancer (NSCLC) treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

This activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis. New and emerging agents may fulfill an unmet need for patients with TNBC. Rapidly evolving evidence in TNBC can present challenges in aligning practice with the latest clinical data and guideline recommendations. This podcast series is designed to provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of TNBC. Participants will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Faculty will also discuss new strategies and approaches to reduce breast cancer mortality and improve the health outcomes of racial/ethnic groups.

Activity Summary:
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a poor prognosis. New and emerging agents may fulfill an unmet need for patients with TNBC. Rapidly evolving evidence in TNBC can present challenges in aligning practice with the latest clinical data and guideline recommendations. This virtual roundtable conversation is designed to provide learners with the opportunity to enhance clinical decision-making skills about the diagnosis and management of TNBC. Participants will review the latest clinical evidence and patient management approaches in TNBC to enhance patient-centered care. Faculty will also discuss new strategies and approaches to reduce breast cancer mortality and improve the health outcomes of racial/ethnic groups.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. This activity is designed to keep healthcare professionals on top of the most recent clinical findings.

This stand alone certified AMA/ANCC/ACPE enduring video will spotlight latest advances in the management of non-small cell lung cancer harboring EGFR Mutations through a 'what you need to know' video featuring a leading expert reporting from the 2023 ESMO Congress.

Activity Summary:
Quarterly Briefs on the Treatment for Early Lung Cancer: A Current Expert Analysis on Important Clinical Decisions is a video commentary discussing the latest study results, conference data and publications in targeted therapy and immunotherapy from the previous 3 months. The activity will be supported by downloadable slides that have the key discussion/teaching points.

Activity Summary:
Conversations and Updates in Gastric/GEJ Cancer is a roundtable discussion designed to inform and guide on the latest breakthroughs to improve patient outcomes.

This activity will involve discussion between key opinion leaders regarding the most recent advances in the second-line and subsequent treatment of gastric/GEJ cancer. The expert faculty will use case scenarios to enhance the learning experience and provide guidance on safely integrating recent progress into practice.

Activity Summary:
Conversations and Updates in Gastric/GEJ Cancer is a roundtable discussion designed to inform and guide on the latest breakthroughs to improve patient outcomes.

This activity will involve discussion between key opinion leaders regarding the most recent advances in the frontline treatment of gastric/GEJ cancer. The expert faculty will use case scenarios to enhance the learning experience and provide guidance on safely integrating recent progress into practice.

Activity Summary:
Conversations in High-Risk NMIBC is a roundtable discussion featuring a urologist and two oncologists. The expert faculty will detail and reflect on recent advances in the treatment and management of high-risk NMIBC.

The activity will be supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
With the recent approval of atezolizumab and osimertinib, and several ongoing trials, it has become clear that immunotherapy and targeted approaches are gaining ground in the adjuvant and neoadjuvant setting of early-stage non-small cell lung cancer (NSCLC). Considering the continual updates from clinical trials in this space, it is pivotal that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.

This activity will highlight the practice-changing updates in adjuvant and neoadjuvant approaches in early-stage NSCLC, to enable safe and effective implementation into clinical practice through expert-guided discussions with Drs. Julie Brahmer, Jamie Chaft and Stephen Liu.

Activity Summary:
Lightning Reports are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings.

This series of certified AMA/ANCC/ACPE enduring videos will spotlight the latest advances in the management of bladder cancer through a series of ‘what you need to know’ videos featuring a leading expert reporting from the 2022 ASCO Annual Meeting.

Activity Summary:
Lightning Reports are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings.

This series of certified AMA/ANCC/ACPE enduring videos will spotlight the latest advances in the management of lung cancer treated with targeted therapy through a series of ‘what you need to know’ videos featuring a leading expert reporting from the 2022 ASCO Annual Meeting.